A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Neoplasms
In brief
The Primary purpose of this study is to identify the recommended Phase 2 dose \[RP2D(s)\] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) in Part 2, to determine one or more additional RP2Ds in Parts 3 and 4.
Key facts
- Study ID
- NCT02908906
- Run by
- Janssen Research & Development, LLC
- People needed
- 234
- Starts
- 2016-11-21
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Parts 1-4: Have an Eastern Cooperative Oncology Group [ECOG] performance status 0 or 1
- Parts 1-4: Has thyroid function laboratory values within normal range
- Parts 1-4: Females of childbearing potential must have a negative serum pregnancy test
- Parts 1-4: Willing and able to adhere to the prohibitions and restrictions specified in this protocol
- For Part 2 only: Participants enrolled into Part 2 must have tumor tissue available for correlative studies. Fresh tumor biopsy is preferred. Archival tissue must meet the following criteria: archival sections within 4 months of sectioning that have been stored at 2 degree to 8 degree Celsius in the dark or archival tumor blocks within 5 years of collection. Participants without tissues meeting the aforementioned archived tissue criteria must undergo a fresh biopsy
- Parts 1 to 4: Have evaluable disease
You may not qualify if…
- Has uncontrolled intercurrent illness, including but not limited to ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure (New York Heart Association class III-IV), unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension or diabetes, or psychiatric illness/social situation that would limited compliance with study requirements
- Has had prior treatment with an anti-Programmed-cell death receptor-1 (PD-1) antibody, anti-the ligand to programmed-cell death 1 (PD-L1) antibody or anti-the ligand to programmed-cell death 2 (PD-L2) antibody
- Treatment with any local or systemic anti-neoplastic therapy, radiotherapy (excluding limited palliative radiation), or investigational anticancer agent within 14 days or 4 half lives, whichever is longer, up to a maximum wash-out period of 28 days prior to the initiation of study drug administration
- Grade 3 or higher toxicity effects from previous treatment with immunotherapy
- A female who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within 5 months after the last dose of study drug
Where it is running
- Study site — St Louis, Missouri, United States
- Study site — Pittsburgh, Pennsylvania, United States
- Study site — Chisinau, Moldova
- Study site — Bialystok, Poland
- Study site — Warsaw, Poland
- Study site — Moscow, Russia
- Study site — Pyatigorsk, Russia
- Study site — Saint Petersburg, Russia
- Study site — Badalona, Spain
- Study site — Barcelona, Spain
- Study site — Madrid, Spain
- Study site — Málaga, Spain
- Study site — Pamplona, Spain
- Study site — Seville, Spain
- Study site — Valencia, Spain
- Study site — Gothenburg, Sweden
- Study site — Glasgow, United Kingdom
- Study site — London, United Kingdom
- Study site — Manchester, United Kingdom
- Study site — Newcastle upon Tyne, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.